Seeing Is Believing
Currently out of the existing stock ratings of Etzer Darout, 54 are a BUY (69.23%), 24 are a HOLD (30.77%).
Analyst Etzer Darout works at BMO with a stock forecast success ratio of 44.84% fulfilled within 114.81 days on average.
Etzer Darout’s has documented 149 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CTMX, CytomX Therapeutics at 01-May-2024.
Analyst best performing recommendations are on FPRX (FIVE PRIME THERAPEUTICS).
The best stock recommendation documented was for MGNX (MACROGENICS) at 7/11/2022. The price target of $4 was fulfilled within 2 days with a profit of $0.45 (12.68%) receiving and performance score of 63.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
8
$4.34 (118.58%)
11
14 days ago
1/5 (20%)
$5.55 (226.53%)
720
Buy
7
$3.34 (91.26%)
10 months 16 days ago
0/2 (0%)
$2.95 (72.84%)
Hold
1 years 10 months 1 days ago
0/2 (0%)
$17.96 (178.88%)
Buy
11
$8.42 (326.36%)
14
2 years 10 months 8 days ago
0/2 (0%)
$6.82 (124.75%)
Buy
38
2 years 10 months 9 days ago
0/1 (0%)
$27.58 (264.68%)
Which stock is Etzer Darout is most bullish on?
Which stock is Etzer Darout is most reserved on?
What Year was the first public recommendation made by Etzer Darout?